RDUS stock forecast
Our latest prediction for Radius Health, Inc.'s stock price was made on the Nov. 6, 2019 when the stock price was at 23.32$.
In the short term (2weeks), RDUS's stock price should outperform the market by 2.88%. During that period the price should oscillate between -8.16% and +11.66%.
In the medium term (3months), RDUS's stock price should underperform the market by -2.09%. During that period the price should oscillate between -19.90% and +27.23%.Get email alerts
Create a solid portfolio with RDUS
About Radius Health, Inc.
Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company's lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA.
At the moment the company generates 173M USD in revenues.
On its last earning announcement, the company reported a loss of -2.89$ per share.
The book value per share is 3.01$
Three months stock forecastNov. 6, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|